Amag Pharmaceuticals Inc Quick Ratio (AMAG) starting from the third quarter 2020 to third quarter 2019, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Amag Pharmaceuticals inc   (NASDAQ: AMAG)

Amag Pharmaceuticals Inc 's Quick Ratio

AMAG's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Amag Pharmaceuticals Inc 's Cash & cash equivalent grew by 14.81 % in the Q3 2020 sequentially, faster than Current Liabilities, this led to improvement in Amag Pharmaceuticals Inc 's Quick Ratio to 1.04, Quick Ratio remained below Amag Pharmaceuticals inc average.

Within Major Pharmaceutical Preparations industry 428 other companies have achieved higher Quick Ratio than Amag Pharmaceuticals Inc in third quarter 2020. While Quick Ratio total ranking has improved so far during the Q3 2020 to 2075, from total ranking in the second quarter 2020 at 2085.

Explain Quick Ratio?
How much Cash & cash equivalents AMAG´s has?
What are AMAG´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AMAG Quick Ratio (Sep 30 2020)
Q3		 (Jun 30 2020)
Q2		 (Mar 31 2020)
Q1		 (Dec 31 2019)
Q4		 (Sep 30 2019)
Q3
Y / Y Current Liabilities Change -20.63 % -34.63 % 2.88 % 25.77 % 5.58 %
Y / Y Cash & cash equivalent Change -11.82 % -43.64 % -53.19 % -56.43 % -55.2 %
Quick Ratio MRQ 1.04 0.91 0.66 0.8 0.94
AMAG's Total Ranking # 2075 # 2085 # 1742 # 1255 # 2205
Seq. Current Liabilities Change 0.61 % -14.47 % -12.24 % 5.11 % -17.14 %
Seq. Cash & cash equivalent Change 14.81 % 17.93 % -27.37 % -10.33 % -26.62 %



Quick Ratio third quarter 2020 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 429
Healthcare Sector # 748
Overall Market # 2075


Quick Ratio Statistics
High Average Low
10.68 3.57 0.66
(Mar 31 2014)   (Mar 31 2020)




Financial Statements
Amag Pharmaceuticals Inc 's Current Liabilities $ 162 Millions Visit AMAG's Balance sheet
Amag Pharmaceuticals Inc 's Cash & cash equivalent $ 169 Millions Visit AMAG's Balance sheet
Source of AMAG's Sales Visit AMAG's Sales by Geography


Cumulative Amag Pharmaceuticals Inc 's Quick Ratio

AMAG's Quick Ratio for the trailling 12 Months

AMAG Quick Ratio

 (Sep 30 2020)
12 Months		 (Jun 30 2020)
12 Months		 (Mar 31 2020)
12 Months		 (Dec 31 2019)
12 Months		 (Sep 30 2019)
12 Months
Y / Y Current Liabilities TTM Growth -9.73 % -3.19 % 3.32 % -12.78 % -25.77 %
Y / Y Cash & cash equivalent TTM Growth -44.98 % -52.93 % -47.96 % -42.28 % -23.15 %
Quick Ratio TTM 0.84 0.83 0.88 1.05 1.38
Total Ranking TTM # 4555 # 1579 # 4564 # 921 # 870
Seq. Current Liabilities TTM Growth -5.48 % -10 % 0.62 % 5.47 % 1.36 %
Seq. Cash & cash equivalent TTM Growth -3.56 % -15.21 % -15.91 % -19.98 % -17.49 %

Quick ratio ranking by company, industry and sector >> Back to AMAG Financial Strength Comparisons >> Go to Compare AMAG Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Amag Pharmaceuticals Inc 's average Cash & cash equivalent, this led to increase in in Amag Pharmaceuticals Inc 's Quick Ratio to 0.84, Quick Ratio remained below AMAG average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 480 other companies have achieved higher Quick Ratio than Amag Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2020 from 1579 to 4555.

Explain Quick Ratio?
How much Cash & cash equivalents AMAG´s has?
What are AMAG´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 481
Healthcare Sector # 922
Within the Market # 4555


trailing twelve months Quick Ratio Statistics
High Average Low
9.47 2.45 0.83
(Sep. 30, 2014)   (Jun 30 2020)




Companies with similar Quick Ratio in the quarter ending Sep 30 2020, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2020 MRQ Cash & cash equivalentSep 30 2020 MRQ Current Liabilities
Oncternal Therapeutics Inc   2.85 $ 21.259  Millions$ 7.472  Millions
Esperion Therapeutics Inc   2.84 $ 215.748  Millions$ 75.947  Millions
Seelos Therapeutics inc   2.84 $ 8.054  Millions$ 2.839  Millions
Legend Biotech Corporation  2.83 $ 455.689  Millions$ 161.167  Millions
Taiwan Liposome Company Ltd   2.77 $ 47.836  Millions$ 17.275  Millions
Hutchmed china Limited  2.75 $ 435.176  Millions$ 158.397  Millions
Rein Therapeutics Inc   2.69 $ 14.121  Millions$ 5.249  Millions
Pharming Group N v   2.67 $ 187.116  Millions$ 70.089  Millions
Dynavax Technologies Corporation  2.66 $ 177.161  Millions$ 66.625  Millions
Cnbx Pharmaceuticals Inc   2.65 $ 1.204  Millions$ 0.455  Millions
Heron Therapeutics Inc   2.65 $ 258.146  Millions$ 97.578  Millions
Igc Pharma Inc   2.63 $ 5.001  Millions$ 1.898  Millions
Disc Medicine Inc   2.60 $ 1.438  Millions$ 0.552  Millions
Talphera Inc   2.60 $ 43.023  Millions$ 16.560  Millions
Urovant Sciences Ltd   2.58 $ 74.401  Millions$ 28.844  Millions
Chembio Diagnostics Inc   2.56 $ 28.687  Millions$ 11.193  Millions
Cns Pharmaceuticals Inc   2.56 $ 1.307  Millions$ 0.511  Millions
Dicerna Pharmaceuticals Inc   2.54 $ 609.913  Millions$ 239.768  Millions
Intec Pharma Ltd   2.54 $ 17.076  Millions$ 6.723  Millions
Biohaven Ltd   2.52 $ 546.214  Millions$ 217.118  Millions
Abeona Therapeutics Inc   2.50 $ 96.871  Millions$ 38.737  Millions
Eton Pharmaceuticals Inc   2.44 $ 7.332  Millions$ 3.000  Millions
Chemomab Therapeutics Ltd   2.27 $ 6.768  Millions$ 2.981  Millions
Puretech Health Plc  2.23 $ 403.881  Millions$ 180.924  Millions
Rezolute Inc   2.20 $ 6.435  Millions$ 2.924  Millions
Affimed N v   2.19 $ 164.476  Millions$ 75.070  Millions
Oncosec Medical Incorporated  2.17 $ 23.976  Millions$ 11.069  Millions
Rigel Pharmaceuticals Inc  2.13 $ 72.812  Millions$ 34.192  Millions
Soligenix inc   2.09 $ 11.343  Millions$ 5.422  Millions
Sellas Life Sciences Group Inc   2.03 $ 8.303  Millions$ 4.083  Millions

Date modified: 2026-09-08T15:10:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.